Episode 7: UCB's $2.2B Deal, EQT Buys Back Desotec for €2B & UniCredit's €35B Hostile Bid for Commerzbank

Welcome to the seventh episode of The Finance Show, Belgium's podcast for corporate finance news, insights, and career guidance.In this episode:Belgian deals:UCB strikes again, acquiring San Diego biotech Candid Therapeutics for up to $2.2 billion, the third major US deal in two months as Belgium's pharma giant deploys its post-debt war chest into next-generation immunology.EQT buys back Desotec from Blackstone for around €2 billion, a textbook private equity story where the same Belgian environmental services champion has been passed between PE funds for the fourth time in 16 years.Global finance:UniCredit officially launches its €35 billion hostile takeover bid for Commerzbank, triggering pushback from Berlin, a 38-slide defensive deck from Commerzbank, and the biggest M&A battle in European banking.New episodes every two weeks.(00:00) Introduction(01:52) UCB, $2.2B Acquisition of Candid Therapeutics(10:29) EQT, €2B Buyback of Desotec from Blackstone(18:13) UniCredit, €35B Hostile Bid for Commerzbank(26:46) ConclusionGet free access to the Tracker: ⁠Tracker⁠Check out our website: ⁠The Finance Show Website⁠